| Value | ₹3.74 Cr |
|---|
BSE filing, NSE: PARMAX. Summary written from the filing by ALFA Finder's alert engine.
Parmax Pharma Ltd: key numbers
- Share price
- ₹135.05
- Market cap
- ₹50.53 Cr
- Revenue (annual)
- ₹12.11 Cr
- Net profit (annual)
- ₹-4.16 Cr
- P/E (TTM)
- -42.3×Sector 46.1×
- Promoter holding
- 64.66%+33.86% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Parmax Pharma Ltd
All →Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Parmax Pharma Other Announcement
Parmax Pharma Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Parmax Pharma Management Change
Parmax Pharma Ltd announced the resignation of Mr. Nikhil Uchat as an Independent Director of the Company, effective October 08, 2026.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd conducted its 32nd Annual General Meeting on September 29, 2026, covering routine business including financial statement adoption and board appointments.
Parmax Pharma Adverse Business Impact
Parmax Pharma reported a major fire incident at its Rajkot plant on September 28, 2026. Two employees were injured, and the company is currently assessing the financial damage.
Parmax Pharma Other Announcement
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Other capital structure change announcements
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr